Sirtuin modulators: past, present, and future perspectives / Francesco Fiorentino, Nicola Mautone, Martina Menna, Francesca D'Acunzo, Antonello Mai, Dante Rotili
Sirtuins are NAD+-dependent protein lysine deacylase and mono-ADP ribosylases present in both prokaryotes and eukaryotes. The sirtuin family comprises seven isoforms in mammals, each possessing different subcellular localization and biological functions. Sirtuins have received increasing attention in the past two decades given their pivotal functions in a variety of biological contexts, including cytodifferentiation, transcriptional regulation, cell cycle progression, apoptosis, inflammation, metabolism, neurological and cardiovascular physiology and cancer. Consequently, modulation of sirtuin activity has been regarded as a promising therapeutic option for many pathologies. In this review, we provide an up-to-date overview of sirtuin biology and pharmacology. We examine the main features of the most relevant inhibitors and activators, analyzing their structure–activity relationships, applications in biology, and therapeutic potential. +.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
Erscheinungsort nicht ermittelbar: 2022 |
| Enthalten in: |
|---|
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Fiorentino, Francesco [VerfasserIn] |
|---|
| Links: |
FID Access [lizenzpflichtig] |
|---|
| Themen: |
Aging |
|---|
| Umfang: |
1 Online-Ressource (25 p) |
|---|
| doi: |
10.4155/fmc-2022-0031 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
KFL011093951 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | KFL011093951 | ||
| 003 | DE-627 | ||
| 005 | 20230713210635.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 230609s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.4155/fmc-2022-0031 |2 doi | |
| 035 | |a (DE-627)KFL011093951 | ||
| 035 | |a (KFL)prod_FICIBQ_10.4155/fmc-2022-0031 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 084 | |a PHARM |q DE-84 |2 fid | ||
| 100 | 1 | |a Fiorentino, Francesco |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Sirtuin modulators: past, present, and future perspectives |c Francesco Fiorentino, Nicola Mautone, Martina Menna, Francesca D'Acunzo, Antonello Mai, Dante Rotili |
| 264 | 1 | |a [Erscheinungsort nicht ermittelbar] |c 2022 | |
| 300 | |a 1 Online-Ressource (25 p) | ||
| 336 | |a nicht spezifiziert |b zzz |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 520 | |a Sirtuins are NAD+-dependent protein lysine deacylase and mono-ADP ribosylases present in both prokaryotes and eukaryotes. The sirtuin family comprises seven isoforms in mammals, each possessing different subcellular localization and biological functions. Sirtuins have received increasing attention in the past two decades given their pivotal functions in a variety of biological contexts, including cytodifferentiation, transcriptional regulation, cell cycle progression, apoptosis, inflammation, metabolism, neurological and cardiovascular physiology and cancer. Consequently, modulation of sirtuin activity has been regarded as a promising therapeutic option for many pathologies. In this review, we provide an up-to-date overview of sirtuin biology and pharmacology. We examine the main features of the most relevant inhibitors and activators, analyzing their structure–activity relationships, applications in biology, and therapeutic potential. + | ||
| 653 | |a aging | ||
| 653 | |a cancer | ||
| 653 | |a drug discovery | ||
| 653 | |a epigenetics | ||
| 653 | |a metabolism | ||
| 653 | |a neurodegeneration | ||
| 653 | |a protein lysine deacylation | ||
| 653 | |a sirtuin modulators | ||
| 653 | |a sirtuins | ||
| 700 | 1 | |a Mautone, Nicola |e verfasserin |4 aut | |
| 700 | 1 | |a Menna, Martina |e verfasserin |4 aut | |
| 700 | 1 | |a D'Acunzo, Francesca |e verfasserin |4 aut | |
| 700 | 1 | |a Mai, Antonello |e verfasserin |4 aut | |
| 700 | 1 | |a Rotili, Dante |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Future medicinal chemistry |d London : Future Science, 2009 |h Online-Ressource |w (DE-627)KFL000006157 |w (DE-600)2572258-X |w (DE-576)398101442 |x 1756-8927 |7 nnns |
| 856 | 4 | 0 | |u http://pharmazie.proxy.fid-lizenzen.de/fid/future-medicine-ejournals-pharmazie/doi.org/10.4155/fmc-2022-0031 |m X:KFL |x Resolving-System |y FID Access |z lizenzpflichtig |
| 912 | |a GBV_KFL | ||
| 912 | |a FID-PHARM | ||
| 935 | |i IMPORT_0628_prod_FICIBQ_03 | ||
| 951 | |a AR | ||